Life Sciences & Biotechnology
Title : | SREBP inhibitors as novel therapeutics for non-alcoholic fatty liver disease: Insights on CRISPER-Cas9 inhibition of SREBPs targeting activated hepatic stellate cells |
Area of research : | Life Sciences & Biotechnology, Medical Sciences |
Focus area : | Non-alcoholic fatty liver disease |
Principal Investigator : | Dr P. Madan Kumar, Scientist, CSIR-Central Food Technological Research Institute (CFTRI), Karnataka |
Timeline Start Year : | 2020 |
Timeline End Year : | 2023 |
Contact info : | director@cftri.res.in |
Details
Executive Summary : | Objective: Evaluating the role of SREBPs and SREBP inhibition in experimental model of NAFLD using ApoE deficient mice. Histological and immunohistochemical analysis of the fatty liver. Determining the effect of SREBP inhibition in HSCs and food bioactive binding induced changes in SREBP stability. Determining the initial toxicity, nutridynamics and nutrikinetics of food SREBP inhibitors. Determining the initial toxicity, nutridynamics and nutrikinetics of food SREBP inhibitors. Determining the effect of SREBP inhibition in HSCs and food bioactive binding induced changes in SREBP stability. Histological and immunohistochemical analysis of the fatty liver. Evaluating the role of SREBPs and SREBP inhibition in experimental model of NAFLD using ApoE deficient mice. |
Organizations involved
